得力生注射液配合调强适形放疗治疗鼻咽癌的临床研究

Intensity-modulated radiation combined with Delisheng injection for naspharyngeal carcinoma

目的探讨得力生注射液在配合调强适形放疗治疗鼻咽癌中的作用。方法66例经病理证实的Ⅱ﹑Ⅲ期鼻咽癌初治患者,随机分为两组:治疗组采用得力生注射液配合调强适形放疗,对照组采用单纯调强适形放疗,比较两组近期疗效、毒副反应、体液免疫指标变化。结果两组近期总有效率无统计学差异(P=0.591);治疗组急性放射性皮炎和急性放射性咽炎发生率明显低于对照组(P=0.035和0.047);治疗组患者治疗后外周血IgG、IgA、IgM有所升高(P<0.05),对照组治疗前后外周血IgG、IgA、IgM变化无显著性差异。结论得力生注射液配合调强适形放疗治疗鼻咽癌可以减轻急性放疗反应,增强患者免疫功能。

Objective To evaluate the therapeutic efficacy of intensity-modulated radiation therapy （IMRT） combined with Delisheng injection for treatment of nasopharyngeal carcinoma （NPC）. Methods Sixty-six patients with pathologically confirmed NPC （stage Ⅱ and Ⅲ） were randomized into therapeutic group and control group. Patients in the therapeutic group were treated with Delisheng injection in addition to IMRT and those in the control group with IMRT alone. Results No significant difference in the response rate occurred between the two groups. The incidence of adverse effects was significantly lower in the therapeutic group than in the control group, and the humoral immunity was improved in the former. Conclusion Delisheng injection can decrease the side effects of IMRT and improve humoral immunity in NPC patients.